RPG Life Sciences Limited
₹2,572.40-₹423.25 (-14.1%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹3,806 Cr
- P/E
- 34.2x
- EV / EBITDA
- 27.7x
- Revenue
- ₹653 Cr
- Net margin
- 15.1%
- ROCE
- 34.4%
Price chart
Technical chartScreen technicals →+5.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -15.3%
- 3M
- -7.4%
- 6M
- +12.0%
- 1Y
- +5.6%
- 5Y
- +264.1%
52-week range
Day change -₹423.25 (-14.1%) from ₹2,996 to ₹2,572 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in RPGLIFE, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 24.9%
Concerns0
Rule-based from financial data. Not advice.
About the company
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally.
Read moreShow less
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
- Sector
- Healthcare
- Shares outstanding
- 1.6 Cr shares
- ISIN
- INE105J01010
- BSE code
- 532983
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹3,806 Cr
- P/E
- 34.2x
- P/B
- 6.9x
- EV / EBITDA
- 27.7x
- EV / Sales
- 6.5x
- P/S
- 6.5x
- Earnings yield
- 2.9%
- 52-week high
- ₹3,090.10
- 52-week low
- ₹1,733.80
Profitability
- Operating margin
- 22.2%
- Net margin
- 15.1%
- EBITDA margin
- 23.4%
- ROE
- 23.5%
- ROCE
- 34.4%
- ROA
- 17.2%
- Dividend payout
- 30.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 5.9%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹653 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 12.2%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 9.1%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹136 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 25.9%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 108.0%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 24.9%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹94.0 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 3.3%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹9.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 22.4%
Solvency and efficiency
- Current ratio
- 2.20
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- Interest coverage
- 129.00
- Financial leverage
- 1.37
- CFO / Net profit
- 1.07
- Cash / Market cap
- 5.6%
- Cash per share
- ₹129.00
- Asset turnover
- 1.13
- Fixed asset turnover
- 5.11
- Capital intensity
- 0.20
- Debtor days
- 31 days
- Inventory turnover
- 1.82
- Cash conversion cycle
- 90 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹28 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹492 Cr |
| Sales | Operating profit | ₹161 Cr |
| Operating profit | Interest | ₹2 Cr |
| Operating profit | Depreciation | ₹21 Cr |
| Operating profit | Profit before tax | ₹138 Cr |
| Other income | Profit before tax | ₹95 Cr |
| Profit before tax | Tax and other | ₹50 Cr |
| Profit before tax | Net profit | ₹183 Cr |
Revenue and net profit
Revenue grew 12.2% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹389 Cr | ₹40 Cr |
| FY2022 | ₹440 Cr | ₹51 Cr |
| FY2023 | ₹513 Cr | ₹68 Cr |
| FY2024 | ₹582 Cr | ₹88 Cr |
| FY2025 | ₹653 Cr | ₹183 Cr |
Cash flows
FY2025: ₹78.0 Cr from operations, ₹36.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹58 Cr | ₹50 Cr |
| FY2022 | ₹65 Cr | ₹30 Cr |
| FY2023 | ₹91 Cr | -₹15 Cr |
| FY2024 | ₹94 Cr | ₹15 Cr |
| FY2025 | ₹78 Cr | ₹36 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹653 Cr+12.2%1Y
- Net profit
- ₹183 Cr+108.0%1Y
- Cash from operations
- ₹78 Cr
- Free cash flow
- ₹36 Cr+140.0%1Y
- Revenue CAGR, 5Y
- 9.1%
- EBITDA CAGR, 5Y
- 19.8%
- Net profit CAGR, 5Y
- 24.9%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹653 Cr | ₹161 Cr | — | ₹183 Cr | ₹78 Cr | ₹36 Cr | 34.5% | +12.2% | +108.0% |
Monthly returns
Month-by-month returns of RPGLIFE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹658 Cr |
| Equity capital | ₹13 Cr |
| Reserves | ₹517 Cr |
| Borrowings | ₹0 Cr |
| Other liabilities | ₹127 Cr |
| Assets | ₹658 Cr |
| Fixed assets | ₹172 Cr |
| Capital work in progress | ₹16 Cr |
| Investments | ₹127 Cr |
| Other assets | ₹343 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
RPGLIFE trades at 34.2x earnings against a peer median of 52.6x (a 35% discount).
Not shown (no positive earnings and no EV / Sales): Dishman Carbogen Amcis Limited, Suven Life Sciences Ltd.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| RPG Life Sciences LimitedRPGLIFEthis companyP/E ↓ discount | ₹3,806 Cr | 34.2x | 6.9x | 23.5% | 27.7x |
| Dishman Carbogen Amcis LimitedDCAL | ₹4,132 Cr | — | 1.0x | -1.9% | 67.5x |
| Artemis Medicare Services LimitedARTEMISMED | ₹4,059 Cr | 42.6x | 4.0x | 10.8% | 32.0x |
| Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,008 Cr | 83.0x | 15.1x | 29.4% | 48.1x |
| INNOVA CAPTAB LIMITEDINNOVACAP | ₹3,945 Cr | 51.8x | 4.6x | 9.4% | 34.2x |
| SENORES PHARMACEUTICALS LIMITEDSENORES | ₹3,750 Cr | 307.0x | 5.2x | 0.6% | 545.5x |
| Indraprastha Medical Corporation LtINDRAMEDCO | ₹3,742 Cr | 21.4x | 5.7x | 25.9% | 17.5x |
| Orchid Pharma LimitedORCHPHARMA | ₹3,739 Cr | 51.8x | 2.8x | — | — |
| Suven Life Sciences Ltd.SUVEN | ₹3,490 Cr | — | 3.3x | -0.9% | -1728.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
RPGLIFE since 1 January, against earlier years.
Historical volatility
RPGLIFE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 18.0% |
| FY2022 | 20.0% |
| FY2023 | 20.0% |
| FY2024 | 22.0% |
| FY2025 | 25.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹653 Cr |
| Costs | |
| Interest | ₹2 Cr |
| Expenses | ₹493 Cr |
| Operating profitOperating Profit | ₹161 Cr |
| Other income and charges | |
| Profit before tax | ₹233 Cr |
| Tax | |
| Net profitNet Profit | ₹183 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹658 Cr |
| Equity capitalEquity Capital | ₹13 Cr |
| Reserves | ₹517 Cr |
| Borrowings | ₹0 Cr |
| Other liabilitiesOther Liabilities | ₹127 Cr |
| AssetsTotal Assets | ₹658 Cr |
| Fixed assetsFixed Assets | ₹172 Cr |
| Capital work in progressCWIP | ₹16 Cr |
| Investments | ₹127 Cr |
| Other assetsOther Assets | ₹343 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹78 Cr |
| Investing cash flowCash from Investing Activity | -₹42 Cr |
| Financing cash flowCash from Financing Activity | -₹27 Cr |
| Change in cashNet Cash Flow | ₹9 Cr |
Learn while you research
Academy chapters picked for RPG Life Sciences Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 34.2, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read